Global epidemiology of diabetes and prediabetes in lean or non-obese patients with NAFLD: a systematic review and meta-analysis.

Ann MedDec 22, 2025 (epub)
Clinical ResearchEndocrinologyGastroenterologyOpen access

Yuan-Yuan Li, Yuan Yu, Hai Bo Jing et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and random-effects meta-analysis estimated the global prevalence of diabetes and prediabetes among people with lean or non-obese non-alcoholic fatty liver disease (NAFLD). Across 54 studies involving 146,714 patients, pooled prevalence was 15.6% (95% CI 10.8%-22.7%) for diabetes and 22.9% (95% CI 12.5%-41.9%) for prediabetes. Prevalence varied by region: diabetes was highest in South American studies, while prediabetes was highest in European studies. Geographic region and mean age were associated with diabetes prevalence; region and country were associated with prediabetes prevalence.

Key findings

  • Pooled diabetes prevalence in lean or non-obese NAFLD was 15.6% (95% CI 10.8%-22.7%).
  • Pooled prediabetes prevalence was 22.9% (95% CI 12.5%-41.9%).
  • Diabetes prevalence was highest in South American studies at 41.3% (CI 39.1%-43.5%); prediabetes was highest in European studies at 34.4% (CI 23.0%-51.4%).
  • Geographic region and mean age jointly accounted for 51.61% of diabetes-prevalence heterogeneity; region and country accounted for 73.65% of prediabetes-prevalence heterogeneity.

Why it matters

The pooled estimates indicate that dysglycaemia is common even among patients with NAFLD who are lean or non-obese. This challenges reliance on obesity as a cue for metabolic risk assessment and supports attention to diabetes and prediabetes in this population. Regional variation and substantial heterogeneity also caution against assuming that a single prevalence estimate applies uniformly across settings.

What to keep in mind

The estimates combine studies with substantial heterogeneity, and prevalence varied by geographic and demographic factors. The abstract does not report study-level quality or explain how differences in populations and methods were addressed.

Source

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.